PL4243824T3 - Profilaktyka i leczenie obrzęku naczynioruchowego - Google Patents

Profilaktyka i leczenie obrzęku naczynioruchowego

Info

Publication number
PL4243824T3
PL4243824T3 PL21805547.3T PL21805547T PL4243824T3 PL 4243824 T3 PL4243824 T3 PL 4243824T3 PL 21805547 T PL21805547 T PL 21805547T PL 4243824 T3 PL4243824 T3 PL 4243824T3
Authority
PL
Poland
Prior art keywords
angioedema
prophylaxis
treatment
Prior art date
Application number
PL21805547.3T
Other languages
English (en)
Inventor
Anne Lesage
Peng Lu
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of PL4243824T3 publication Critical patent/PL4243824T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21805547.3T 2020-11-12 2021-11-12 Profilaktyka i leczenie obrzęku naczynioruchowego PL4243824T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
PL4243824T3 true PL4243824T3 (pl) 2026-05-18

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21805547.3T PL4243824T3 (pl) 2020-11-12 2021-11-12 Profilaktyka i leczenie obrzęku naczynioruchowego

Country Status (13)

Country Link
US (1) US12629363B2 (pl)
EP (1) EP4243824B1 (pl)
JP (1) JP2023549849A (pl)
KR (1) KR20230107269A (pl)
CN (1) CN116685353A (pl)
AU (1) AU2021376885A1 (pl)
CA (1) CA3198246A1 (pl)
ES (1) ES3061585T3 (pl)
IL (1) IL302887A (pl)
MX (1) MX2023005563A (pl)
PL (1) PL4243824T3 (pl)
WO (1) WO2022101395A1 (pl)
ZA (1) ZA202305122B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
HRP20260166T1 (hr) * 2022-03-25 2026-03-27 Pharvaris Gmbh Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora
EP4745196A1 (en) 2023-08-16 2026-05-20 LG Chem, Ltd. RESIN COMPOSITION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
KR20230107269A (ko) 2023-07-14
JP2023549849A (ja) 2023-11-29
CN116685353A (zh) 2023-09-01
ZA202305122B (en) 2024-08-28
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
EP4243824C0 (en) 2025-12-24
US20230338358A1 (en) 2023-10-26
IL302887A (en) 2023-07-01
MX2023005563A (es) 2023-09-11
EP4243824B1 (en) 2025-12-24
AU2021376885A1 (en) 2023-06-08
CA3198246A1 (en) 2022-05-19
US12629363B2 (en) 2026-05-19
EP4243824A1 (en) 2023-09-20